<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690090</url>
  </required_header>
  <id_info>
    <org_study_id>Enox-TOH-0001-RP</org_study_id>
    <nct_id>NCT02690090</nct_id>
  </id_info>
  <brief_title>Safety Study of Enoxaparin Prophylaxis in Critically Ill Adults With Severe Renal Insufficiency</brief_title>
  <official_title>Phase 4 Study Determining the Safety of Enoxaparin Prophylaxis in Critically Ill Adults With Severe Renal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ottawa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators study is the first step (a pilot study) in determining whether the&#xD;
      manufacturer's recommended dose of a blood thinner called enoxaparin, in adults who are&#xD;
      patients in an intensive care unit and have severely reduced kidney function (less than or&#xD;
      equal to approximately 30% of their normal function) is safe with respect to the adverse&#xD;
      effect of bleeding.&#xD;
&#xD;
      The investigators hypothesis is that studying these patients, going forward in time, without&#xD;
      interfering with their care, to eventually determine if this blood thinner is safe at reduced&#xD;
      doses, is feasible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      To determine the feasibility of conducting a single centre, open-label, prospective study to&#xD;
      inform preparation for a prospective phase III study evaluating the efficacy &amp; safety of&#xD;
      enoxaparin prophylaxis in critically ill adults with creatinine clearance &lt; 30 mL/min.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      A pilot open-label, single-arm, prospective study.&#xD;
&#xD;
      Patients:&#xD;
&#xD;
      Critically ill adults (&gt; 18 years) with creatinine clearance &lt; 30 mL/min.&#xD;
&#xD;
      Setting:&#xD;
&#xD;
      The Ottawa Hospital Intensive Care Units&#xD;
&#xD;
      Sample Size: n=30.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Study patients will receive enoxaparin 30 mg S.C. daily for VTE prophylaxis as directed by&#xD;
      their responsible Intensivist. The investigators are not directing this clinical intervention&#xD;
      in any manner.&#xD;
&#xD;
      Primary/Feasibility Outcomes: screening and enrolment rates with a goal of recruiting at&#xD;
      least 5 patients collectively, from both ICUs, per month.&#xD;
&#xD;
      Secondary/Clinical Outcomes: Determining the accumulation of anti-Xa concentrations, if any,&#xD;
      recording of the rates of major bleeding, VTE, and HIT during the study.&#xD;
&#xD;
      Trial Duration:&#xD;
&#xD;
      Anticipated 24 months.&#xD;
&#xD;
      Analysis:&#xD;
&#xD;
      Statistical analysis will be performed using SAS software through the Ottawa Hospital Methods&#xD;
      Centre. Patient demographics and clinical baseline characteristics will be described.&#xD;
      Continuous variables will be presented as mean (SD), ordinal variables as medians (IQR) and&#xD;
      categorical variables as proportions. Cox proportional hazards analysis will be used to&#xD;
      evaluate an association between trough anti-Xa levels and major bleeding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the rate of patient enrollment into this study within the 24 month allotted time frame of recruitment</measure>
    <time_frame>24 months</time_frame>
    <description>This is a pilot feasibility study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure bioaccumulation of Enoxaparin, if any, defined as at least one trough anti-Xa level measuring &gt; 0.4 IU/mL</measure>
    <time_frame>24 hours</time_frame>
    <description>Trough Anti-Xa concentration at baseline, 4, 8, 12, 16 &amp; 24 hours of ICU day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record incidence of major bleeding episodes using the HEME bleeding assessment tool</measure>
    <time_frame>Daily until ICU discharge or a maximum of the first 10 days of ICU stay, whichever is less</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record incidence of VTE</measure>
    <time_frame>Daily until ICU discharge or a maximum of the first 10 days of ICU stay, whichever is less</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure bioaccumulation of Enoxaparin, if any, defined as at least one trough anti-Xa level measuring &gt; 0.4 IU/mL</measure>
    <time_frame>ICU stay until discharge or a maximum of the first 10 days of ICU stay, whichever is less</time_frame>
    <description>Trough Anti-Xa concentration will be measured on days; 2, 3, 4, 7 &amp; day of ICU discharge or ICU day 10, whichever is less</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>enoxaparin</arm_group_label>
    <description>enoxaparin prophylaxis as directed by treating Intensivist</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        adult critically ill patients with creatinine clearance &lt; 30 mL/min and requiring&#xD;
        thromboprophylaxis during their ICU course.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  body weight ≥ 45 kg&#xD;
&#xD;
          -  expected ICU length of stay ≥ 72 hours&#xD;
&#xD;
          -  severe renal insufficiency, defined by calculated creatinine clearance (CrCl) &lt; 30&#xD;
             mL/min using the Cockcroft-Gault formula&#xD;
&#xD;
          -  All patients with severe renal insufficiency at ICU admission will be included,&#xD;
             regardless of chronicity of renal disease. This includes patients with pre-existing&#xD;
             dialysis dependence via intermittent hemodialysis and peritoneal dialysis; patients&#xD;
             with acute kidney injury requiring SLED (sustained low-efficiency dialysis) will also&#xD;
             be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  neurological surgery in last 3 months&#xD;
&#xD;
          -  epidural catheter insertion within previous 12 hours&#xD;
&#xD;
          -  ICU admission &gt; 2 weeks&#xD;
&#xD;
          -  receipt of &gt; 2 doses of LMWH while in ICU or in hospital within 7 days prior to study&#xD;
             enrolment&#xD;
&#xD;
          -  active bleeding; platelet count &lt; 50 x 109/L&#xD;
&#xD;
          -  INR or aPTT &gt; 2 times the upper limit of normal&#xD;
&#xD;
          -  need for therapeutic anticoagulation; previous adverse reaction to heparin based&#xD;
             products&#xD;
&#xD;
          -  contraindication to blood product transfusion&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
&#xD;
          -  life expectancy &lt; 2 weeks or receiving palliative care&#xD;
&#xD;
          -  previous enrolment in current study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rakesh V Patel, MD PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rakesh V Patel, M.D.</last_name>
    <phone>613.737.8899</phone>
    <phone_ext>78701</phone_ext>
    <email>rpatel@toh.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Carrier, M.D.</last_name>
    <email>mcarrier@toh.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh V Patel, MD</last_name>
      <phone>613.737.9830</phone>
      <email>rpatel@ohri.ca</email>
    </contact>
    <contact_backup>
      <last_name>Lana A Castellucci, MD</last_name>
      <phone>613.737.9830</phone>
      <email>lcastellucci@ohri.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Rakesh V Patel, MD PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Critically ill adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

